Cargando…
Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers
Pancreatic cancer is an increasing cause of cancer related death worldwide. KRAS is the dominant oncogene in this cancer type and molecular rationale would indicate, that inhibitors of the downstream target MEK could be appropriate targeted agents, but clinical trials have failed so far to achieve s...
Autores principales: | Brauswetter, Diána, Gurbi, Bianka, Varga, Attila, Várkondi, Edit, Schwab, Richárd, Bánhegyi, Gábor, Fábián, Orsolya, Kéri, György, Vályi-Nagy, István, Peták, István |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619833/ https://www.ncbi.nlm.nih.gov/pubmed/28957417 http://dx.doi.org/10.1371/journal.pone.0185687 |
Ejemplares similares
-
MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers
por: Gurbi, Bianka, et al.
Publicado: (2023) -
The Potential Impact of Connexin 43 Expression on Bcl-2 Protein Level and Taxane Sensitivity in Head and Neck Cancers–In Vitro Studies
por: Gurbi, Bianka, et al.
Publicado: (2019) -
Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support
por: Szkukalek, Judita, et al.
Publicado: (2021) -
Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC
por: Urbán, László, et al.
Publicado: (2020) -
Targeted drug combination therapy design based on driver genes
por: Zsákai, Lilian, et al.
Publicado: (2019)